3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
16
Lung Neoplasms
8
Lymphoma, Large-Cell, Anaplastic
4
Carcinoma
3
Brain Neoplasms
2
ALK-positive Advanced NSCLC
2
Neuroma, Acoustic
1
Neurofibromatosis 2
1
Neoplasms
1
Neoplasm Metastasis
1
NSCLC
1
Meningioma
1
Granuloma, Plasma Cell
1
Gastrointestinal Neoplasms
1
Ependymoma
1
Disease Progression
1
Carcinoma, Squamous Cell
1
Carcinoma, Pancreatic Ductal
1
Carcinoma, Large Cell
1
Breast Neoplasms
1
Adenocarcinoma
1
ALK+ Advanced NSCLC
1
Interventions
Oxaliplatin
29
Fluorouracil
25
Leucovorin
20
Capecitabine
18
Irinotecan
17
Bevacizumab
14
Cisplatin
12
Surveys and Questionnaires
11
Gemcitabine
9
Drug Therapy
9
Standard of Care
8
Nivolumab
7
Cetuximab
7
pembrolizumab
6
S 1 (combination)
6
Cyclophosphamide
6
atezolizumab
5
Specimen Handling
5
Endoscopic Mucosal Resection
5
Educational Status
5
Docetaxel
5
Blood Specimen Collection
5
fludarabine
4
aldesleukin
4
Radiotherapy
4
Radiosurgery
4
Pemetrexed
4
IFL protocol
4
Folfox protocol
4
Everolimus
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Gastrointestinal Neoplasms
×
brigatinib
×
Clear all
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled